Report copyright - Novel Immunotherapeutic Approaches in mRCC - euikcs.com · Eligibility: metastatic clear cell RCC, no prior systemic rx Assess: •T cell infiltrate •PD-L1 expression Baseline primary
Please pass captcha verification before submit form